According to diabetes news, the pharmaceutical giant GlaxoSmithKline may have to pay as much as 1 billion dollars to settle side-effect claims regarding their diabetic medication Avandia . The first legal cases concerning the drug are currently on the verge of being settled.
Some 700 plaintiffs have banded together, and the diabetes drug company will likely settle out of court for around 60 million dollars. Andrew Witty, the chief executive of GSK, is looking to close cases as soon as possible.
However, with the potential for some 13,000 lawsuits in total, Glaxo may face a final settlement fee in excess of 1 billion dollars. This estimate is in itself lower than some previous forecasts of up to 6 billion dollars. A clinical trial regarding the safety of the drug is still underway.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…